The Antibiotics Jam: Community Acquired Pneumonia and Skin Infections

Subscribe on iTunes

This week: Empiric antibiotic choices for community acquired pnuemonia and clindamycin versus trimethoprim-sulfamethoxazole for skin and soft tissue infections.

Fahad and Amol want you to understand the following:

1. A large, high quality RCT showed that there was no significant difference between an empiric treatment strategy of beta-lactam vs beta-lactam plus macrolide vs respiratory fluoroquinolone for the treatment of community-acquired pneumonia requiring hospitalization in a non-ICU setting. 

2. A high quality RCT showed that there was no significant difference between clindamycin and TMP-SMX, with respect to either efficacy or side-effect profile, for the treatment of uncomplicated skin infections in regions with endemic Methicillin-Resistant Staphylococcus Aureus. 

Continuing Medical Education

Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.

The papers

DF Postma et al. Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults. N Engl J Med. 2015 Apr 2;372(14):1312-23. (PubMed).

LG Miller et al. Clindamycin versus Trimethoprim–Sulfamethoxazole for Uncomplicated Skin Infections. N Engl J Med. 2015 Mar 19;372(12):1093-103. (PubMed).

Good stuff

Anglo-Saxon remedy kills hospital superbug MRSA. Clare Wilson. New Scientist. 30 Mar 2015.

Genetically Determined Height and Coronary Artery Disease.

Clinical Pearl Jam

Surviving Sepsis Campaign Guideline revised.

Leave a Comment

Your email address will not be published. Required fields are marked *

Republish this article

Republish this article on your website under the creative commons licence.

Learn more